Our top pick for
US stocks

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Biotron is a biotechnology business based in Australia. Biotron shares (BIT) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Biotron has a trailing 12-month revenue of around $1.4 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Long-term investing
Our top pick for
Low-cost broker
52-week range | $0.046 - $0.115 |
---|---|
50-day moving average | $0.0804 |
200-day moving average | $0.0724 |
Target price | N/A |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-0.004 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.063
1 week (2022-06-21) | -1.56% |
---|---|
1 month (2022-05-27) | -37.00% |
3 months (2022-03-28) | -21.25% |
6 months (2021-12-24) | -32.26% |
1 year (2021-06-28) | 31.25% |
---|---|
2 years (2020-06-26) | -19.23% |
3 years (2019-06-28) | -4.55% |
5 years (2017-06-28) | 229.84% |
Revenue TTM | $1.4 million |
---|---|
Gross profit TTM | $1.5 million |
Return on assets TTM | -43.38% |
Return on equity TTM | -83.21% |
Profit margin | -193.68% |
Book value | 0.003 |
Market capitalisation | $53.4 million |
TTM: trailing 12 months
We're not expecting Biotron to pay a dividend over the next 12 months.
Biotron's shares were split on 27 March 2006.
Over the last 12 months, Biotron's shares have ranged in value from as little as $0.046 up to $0.115. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Biotron's is -1.7355. This would suggest that Biotron's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biotron has bucked the trend.
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.
Steps to owning and managing Kincora Copper shares.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.